The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial’s global footprint to over 80 sites, up from the current 60 in North America, with patient screening and enrollment in these new regions expected to begin in Q2 2026.

The study evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma/LBCL who show minimal residual disease/MRD after initial chemotherapy. The decision to expand follows positive interim futility analysis data from the first 24 patients, which showed that cema-cel achieved a 58.3% MRD clearance rate compared to just 16.7% in the standard-of-care observation group. Additionally, the therapy was well-tolerated with no reported cases of cytokine release syndrome or neurotoxicity.

Allogene Therapeutics Inc. (NASDAQ:ALLO) aims to enroll ~220 patients in the ALPHA3 trial by the end of 2027. An interim analysis of event-free survival is planned for mid-2027, with the primary analysis following in mid-2028 to potentially support a BLA submission. Cema-cel, which has already received the RMAT designation from the FDA, represents a next-generation off-the-shelf AlloCAR T product designed to address the 30% of LBCL patients who typically relapse under the current watch-and-wait standard of care.

Allogene Therapeutics Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.

While we acknowledge the potential of ALLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.